Related Experiment Video
Updated: Aug 15, 2026

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
Cellular retinoic acid-binding protein 2 is down-regulated in prostate cancer
Ali Fuat Okuducu1, Viktor Janzen, Yon Ko
1Institute of Pathology, University of Bonn, D-53011 Bonn, Germany.
Abstract:
Prostate cancer is among the most frequent tumours in industrialized nations and many questions remain open concerning the molecular events underlying its development and progression. In the present study we have combined cDNA array hybridization to laser-assisted microdissection (LAM) in order to investigate differences in gene expression between epithelial and stromal cells of prostate cancer and normal peripheral prostate tissue. Results have been verified for selected candidate genes by quantitative real-time RT-PCR. Using this approach and immunohistochemistry we could demonstrate a down-regulation of cellular retinoic acid binding protein 2 (CRABP2) mRNA and protein in carcinoma cells compared to normal glandular cells. CRABP2 is a main regulator of anti-carcinogenic activities of retinoic acid and may become a novel diagnostic marker and experimental therapeutic tool for prostate cancer. In addition, results of cDNA array hybridization suggest an up-regulation of 34 further genes and a down-regulation of 6 genes in cancer tissues compared to normal peripheral prostate tissues. Several of these genes have already been reported to be associated with carcinogenesis in organs such as the prostate.
Insights
Cellular retinoic acid binding protein 2 (CRABP2) is down-regulated in prostate cancer cells, suggesting its potential as a diagnostic marker and therapeutic target for this common malignancy.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Prostate cancer is a prevalent malignancy in industrialized nations.
- The molecular mechanisms driving prostate cancer development and progression require further elucidation.
Purpose of the Study:
- To investigate differential gene expression between prostate cancer and normal prostate tissues.
- To identify molecular markers associated with prostate cancer development and progression.
Main Methods:
- Combined cDNA array hybridization and laser-assisted microdissection (LAM).
- Quantitative real-time RT-PCR for result verification.
- Immunohistochemistry to assess protein expression.
Main Results:
- Demonstrated down-regulation of cellular retinoic acid binding protein 2 (CRABP2) mRNA and protein in prostate cancer cells compared to normal glandular cells.
- Identified CRABP2 as a key regulator of retinoic acid's anti-carcinogenic effects.
- Observed up-regulation of 34 genes and down-regulation of 6 genes in cancer tissues.
Conclusions:
- CRABP2 represents a potential novel diagnostic marker and therapeutic tool for prostate cancer.
- The identified gene expression changes offer insights into prostate carcinogenesis.
- Further research into CRABP2 and other differentially expressed genes is warranted.
Related Concept Videos
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Negative Regulator Molecules
Abnormal Proliferation

